Janney Montgomery Scott LLC Buys Shares of 110,240 Health Catalyst, Inc. (NASDAQ:HCAT)

Janney Montgomery Scott LLC acquired a new stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 110,240 shares of the company's stock, valued at approximately $897,000. Janney Montgomery Scott LLC owned 0.18% of Health Catalyst at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of HCAT. Primecap Management Co. CA raised its stake in Health Catalyst by 14.7% in the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company's stock worth $15,205,000 after buying an additional 305,079 shares in the last quarter. Kennedy Capital Management LLC bought a new stake in shares of Health Catalyst during the 1st quarter valued at $8,780,000. Acadian Asset Management LLC increased its stake in shares of Health Catalyst by 38.3% in the 1st quarter. Acadian Asset Management LLC now owns 724,560 shares of the company's stock worth $5,453,000 after acquiring an additional 200,494 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in Health Catalyst during the 3rd quarter valued at about $2,012,000. Finally, AQR Capital Management LLC bought a new stake in Health Catalyst during the second quarter worth about $564,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Citigroup increased their target price on Health Catalyst from $9.00 to $10.50 and gave the stock a "buy" rating in a research note on Wednesday. Evercore ISI lifted their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Tuesday, October 8th. Stephens upped their price target on Health Catalyst from $7.00 to $9.00 and gave the company an "equal weight" rating in a report on Thursday. Piper Sandler reduced their price objective on Health Catalyst from $14.00 to $11.00 and set an "overweight" rating for the company in a report on Monday, August 26th. Finally, Royal Bank of Canada upped their target price on shares of Health Catalyst from $8.00 to $9.00 and gave the company a "sector perform" rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.71.

Health Catalyst Stock Performance

Shares of Health Catalyst stock traded down $0.80 during trading on Friday, reaching $7.65. 735,511 shares of the stock traded hands, compared to its average volume of 548,477. The business has a fifty day simple moving average of $8.16 and a two-hundred day simple moving average of $7.22. Health Catalyst, Inc. has a 52-week low of $5.42 and a 52-week high of $11.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million for the quarter, compared to analysts' expectations of $76.27 million. During the same period last year, the company earned ($0.22) earnings per share. The firm's revenue was up 3.5% on a year-over-year basis. On average, equities research analysts anticipate that Health Catalyst, Inc. will post -0.35 EPS for the current fiscal year.

Insider Activity

In other Health Catalyst news, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the transaction, the chief operating officer now directly owns 140,108 shares of the company's stock, valued at $1,062,018.64. The trade was a 5.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,068 shares of company stock worth $257,555. 2.50% of the stock is currently owned by corporate insiders.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.